On 22 March 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Juluca, intended for the treatment of HIV infection. The applicant for this medicinal product is ViiV Healthcare UK Limited.
Juluca is a fixed-dose combination of two active substances, dolutegravir and rilpivirine, and will be available as 50 mg/25 mg film-coated tablets. Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral DNA integration which is essential for HIV replication. Rilpivirine activity is mediated by non-competitive inhibition of HIV-1 reverse transcriptase.
The benefit with Juluca is its ability to maintain viral suppression of HIV strains that lack resistance (documented or clinically suspected) to integrase inhibitors. The most common side effects are insomnia, headache, dizziness, nausea and diarrhoea.
The full indication is: “Juluca is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically-suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor (see section 5.1).”
It is proposed that Juluca be prescribed by physicians experienced in the management of HIV infection.
For more information and fast delivery of the life-saving, latest FDA approved oncology drugs, please contact us at firstname.lastname@example.org
We are a Swiss pharmaceutical wholesaler, specialised in sourcing and delivering pharma products, medical devices and drugs from and to all over the world.